The data reported and discussed in this paper indicate that this new immunoreagent meets several criteria for a potential anticancer compound: it is human, hence poorly or not immunogenic; it binds selectively and with good affinity to a CEA epitope expressed on human tumors, including melanoma, metastatic melanoma, lung, breast and colon carcinomas. The gene discussed is CEACAM5; the disease is metastatic melanoma.